Table 2. Cohort description.
| Patients (n = 212) | ||
|---|---|---|
| Demographics | ||
| Age (median, range) | 60 | 18–93 |
| Male (n,%) | 106 | 50 |
| History of previous seizures (n,%) | 104 | 49.1 |
| Center (n,%) | ||
| CHUV | 104 | 49.1 |
| BWH | 65 | 30.7 |
| MGH | 30 | 14.2 |
| BIDMC | 13 | 6.1 |
| SE characteristics | ||
| Worst seizure type (n,%) | ||
| Focal without consciousness impairment | 32 | 15.1 |
| Focal with consciousness impairment | 57 | 28.9 |
| Absence | 3 | 1.42 |
| Myoclonic | 1 | 0.5 |
| Generalized convulsive | 102 | 48.1 |
| Nonconvulsive SE in coma | 17 | 8 |
| Level of consciousness before treatment (n,%) | ||
| Alert | 24 | 11.3 |
| Confused | 51 | 24.1 |
| Somnolent | 13 | 6.1 |
| Stuporous | 88 | 41.5 |
| Comatose | 36 | 17 |
| STESS (mean, SD) | 2.64 | 1.63 |
| Refractory SE (n,%) | 119 | 56.12 |
| Number of different ASD used (median, range) | 3 | 0–13 |
| Coma induction for SE control (n,%) | 24 | 11.3 |
| Outcome at discharge (n,%) | ||
| Return to clinical premorbid baseline | 96 | 45.3 |
| New morbidity | 89 | 42 |
| Death | 27 | 12.8 |
ASD, antiseizure drug; BWH, Brigham and Women’s Hospital; BIDMC, Beth Israel Deaconess Medical Center; CHUV, Lausanne University Hospital; MGH, Massachusetts General Hospital; STESS, Status Epilepticus Severity Score.